Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report

Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report

ALK gene rearrangements are detected in approximately 3% to 5% of NSCLC. ALK tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in ALK-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fata...

Full description

Bibliographic Details
Main Authors: James A. Fletcher, M.B.B.S., William J. Mullally, MBBCh BAO, Rahul Ladwa, MPhil, Kenneth J. O’Byrne, MD
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:JTO Clinical and Research Reports
Subjects:
Lorlatinib
Alectinib
Pneumonitis
NSCLC
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001340

Similar Items

Similar Items